Search
Skip to Search Results- 1Alsagheir, Ali I
- 1Gupta, Nancy
- 1Molavi, Ommoleila
- 1O'Shea, Daire T
- 1Potts, Kyle G
- 1St.Vincent, Mireille RM
-
Investigating Radiation in Combination with Oncolytic Vaccinia Virus to Improve the Treatment of Glioblastoma
DownloadFall 2023
Glioblastoma (GBM) is a malignant and immune-suppressed brain cancer that remains incurable despite the current standard of care. Radiotherapy is a mainstay of GBM treatment, however invasive cancer cells outside the irradiated field and radioresistance preclude complete eradication of GBM cells....
-
Spring 2021
Vaccinia virus (VACV) has shown promise as an oncolytic agent for treating a variety of tumour types, with preliminary results suggesting that this strategy holds promise for treating breast cancer. Our lab has previously modified VACV by deleting virally-encoded enzymes responsible for dNTP...
-
Characterization of the Humoral Immune Response Elicited Against a Prophylactic Vaccine Composed of Recombinant Envelope Glycoproteins from Hepatitis C Virus
DownloadFall 2018
A global prophylactic vaccine for Hepatitis C Virus (HCV) remains elusive. The diversity of the virus is a major hurdle; a successful vaccine will need to protect against all 7 HCV genotypes (gt). Our lab is developing a vaccine comprising the two envelope glycoproteins of HCV (E1E2). An...
-
Spring 2017
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), continues to be a leading infectious cause of death worldwide with approximately 10 million new cases and 2 million deaths attributed annually. There has been resurgence in active TB infections since 1980s and the World Health...
-
Deletion of F4L (ribonucleotide reductase) in Vaccinia Virus Produces a Selective Oncolytic Virus and Promotes Anti-tumor Immunity with Superior Safety in Bladder Cancer
DownloadFall 2017
Overall recurrence of non-muscle-invasive bladder cancer (NMIBC) can be as high as 80% within 5 years of initial treatment. High-grade NMIBC has the greatest risk of recurrence and treatment for these patients includes surgery followed by intravesical therapy with the immunotherapeutic agent...
-
Differentiation of human embryonic stem cells into hepatocytes and their in vivo application for hepatitis C viral production
DownloadFall 2014
Abstract Introduction: Chronic hepatitis C virus (HCV) infection is a global problem. The World Health Organization estimates that about 170 million individuals around the world are infected with HCV. Chronic HCV has a high rate of morbidity and mortality due to cirrhosis and hepatocellular...
-
Novel Agents Inhibiting Hepatitis C Virus; Application to Prevention of Re-infection after Liver Transplantation
DownloadFall 2013
Recurrent Hepatitis C virus infection drives inferior outcomes experienced by patients undergoing liver transplantation due to HCV-associated liver disease. Existing therapies exhibit increased toxicity, poor efficacy, and profound patient intolerability in the immediate transplantation period....
-
The Discovery and Characterization of Rigid Amphipathic Fusion Inhibitors (RAFIS), a Novel Class of Broad-Spectrum Antiviral Compounds
DownloadSpring 2012
Antiviral drugs targeting viral proteins or their interactions with cellular proteins lead to rapid selection for resistance. Moreover, the number of viral targets is limited. Novel antiviral targets are needed. The unique characteristics of fusion between virion envelopes and cell membranes may...
-
Fall 2012
Approximately 70% of patients infected with hepatitis C virus (HCV) develop chronic infection, which has been reported to be due to impaired specific T cell responses. Myeloid dendritic cells (mDCs) are potent antigen-presenting cells that regulate T cell responses, however their role during...
-
Delivery of STAT3 inhibitor cucurbitacins to tumor by polymeric nano-carriers : Implications in cancer chemo- and immunotherapy
DownloadFall 2009
Signal Transducer and Activator of Transcription 3 (STAT3), a common oncogenic mediator, is constitutively activated in many types of human cancers and plays a critical role in tumor growth and cancer immune evasion. The focus of this dissertation is the delivery of STAT3 inhibitor cucurbitacins...